RT Journal Article SR Electronic T1 Large-scale genome-wide association study of 398,238 women unveils seven novel loci associated with high-grade serous epithelial ovarian cancer risk JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2024.02.29.24303243 DO 10.1101/2024.02.29.24303243 A1 Barnes, Daniel R. A1 Tyrer, Jonathan P. A1 Dennis, Joe A1 Leslie, Goska A1 Bolla, Manjeet K. A1 Lush, Michael A1 Aeilts, Amber M. A1 Aittomäki, Kristiina A1 Andrieu, Nadine A1 Andrulis, Irene L. A1 Anton-Culver, Hoda A1 Arason, Adalgeir A1 Arun, Banu K. A1 Balmaña, Judith A1 Bandera, Elisa V. A1 Barkardottir, Rosa B. A1 Berger, Lieke P.V. A1 Berrington de Gonzalez, Amy A1 Berthet, Pascaline A1 Białkowska, Katarzyna A1 Bjørge, Line A1 Blanco, Amie M. A1 Blok, Marinus J. A1 Bobolis, Kristie A. A1 Bogdanova, Natalia V. A1 Brenton, James D. A1 Butz, Henriett A1 Buys, Saundra S. A1 Caligo, Maria A. A1 Campbell, Ian A1 Castillo, Carmen A1 Claes, Kathleen B.M. A1 GEMO Study Collaborators A1 EMBRACE Collaborators A1 Colonna, Sarah V. A1 Cook, Linda S. A1 Daly, Mary B. A1 Dansonka-Mieszkowska, Agnieszka A1 de la Hoya, Miguel A1 deFazio, Anna A1 DePersia, Allison A1 Ding, Yuan Chun A1 Domchek, Susan M. A1 Dörk, Thilo A1 Einbeigi, Zakaria A1 Engel, Christoph A1 Evans, D. Gareth A1 Foretova, Lenka A1 Fortner, Renée T. A1 Fostira, Florentia A1 Foti, Maria Cristina A1 Friedman, Eitan A1 Frone, Megan N. A1 Ganz, Patricia A. A1 Gentry-Maharaj, Aleksandra A1 Glendon, Gord A1 Godwin, Andrew K. A1 González-Neira, Anna A1 Greene, Mark H. A1 Gronwald, Jacek A1 Guerrieri-Gonzaga, Aliana A1 Hamann, Ute A1 Hansen, Thomas v.O. A1 Harris, Holly R. A1 Hauke, Jan A1 Heitz, Florian A1 Hogervorst, Frans B.L. A1 Hooning, Maartje J. A1 Hopper, John L. A1 Huff, Chad D A1 Huntsman, David G. A1 Imyanitov, Evgeny N. A1 kConFab Investigators A1 Izatt, Louise A1 Jakubowska, Anna A1 James, Paul A. A1 Janavicius, Ramunas A1 John, Esther M. A1 Kar, Siddhartha A1 Karlan, Beth Y. A1 Kennedy, Catherine J. A1 Kiemeney, Lambertus A.L.M. A1 Konstantopoulou, Irene A1 Kupryjanczyk, Jolanta A1 Laitman, Yael A1 Lavie, Ofer A1 Lawrenson, Kate A1 Lester, Jenny A1 Lesueur, Fabienne A1 Lopez-Pleguezuelos, Carlos A1 Mai, Phuong L. A1 Manoukian, Siranoush A1 May, Taymaa A1 McNeish, Iain A. A1 Menon, Usha A1 Milne, Roger L. A1 Modugno, Francesmary A1 Mongiovi, Jennifer M. A1 Montagna, Marco A1 Moysich, Kirsten B. A1 Neuhausen, Susan L. A1 Nielsen, Finn C. A1 Noguès, Catherine A1 Oláh, Edit A1 Olopade, Olufunmilayo I. A1 Osorio, Ana A1 Papi, Laura A1 Pathak, Harsh A1 Pearce, Celeste L. A1 Pedersen, Inge S. A1 Peixoto, Ana A1 Pejovic, Tanja A1 Peng, Pei-Chen A1 Peshkin, Beth N. A1 Peterlongo, Paolo A1 Powell, C. Bethan A1 Prokofyeva, Darya A1 Pujana, Miquel Angel A1 Radice, Paolo A1 Rashid, Muhammad U. A1 Rennert, Gad A1 Richenberg, George A1 Sandler, Dale P. A1 Sasamoto, Naoko A1 Setiawan, Veronica W. A1 Sharma, Priyanka A1 Sieh, Weiva A1 Singer, Christian F. A1 Snape, Katie A1 Sokolenko, Anna P. A1 Soucy, Penny A1 Southey, Melissa C. A1 Stoppa-Lyonnet, Dominique A1 Sutphen, Rebecca A1 Sutter, Christian A1 Teixeira, Manuel R. A1 Terry, Kathryn L. A1 Thomsen, Liv Cecilie V. A1 Tischkowitz, Marc A1 Toland, Amanda E. A1 Van Gorp, Toon A1 Vega, Ana A1 Velez Edwards, Digna R. A1 Webb, Penelope M. A1 Weitzel, Jeffrey N. A1 Wentzensen, Nicolas A1 Whittemore, Alice S. A1 Winham, Stacey J. A1 Wu, Anna H. A1 Yadav, Siddhartha A1 Yu, Yao A1 Ziogas, Argyrios A1 Berchuck, Andrew A1 Couch, Fergus J. A1 Goode, Ellen L. A1 Goodman, Marc T. A1 Monteiro, Alvaro N. A1 Offit, Kenneth A1 Ramus, Susan J. A1 Risch, Harvey A. A1 Schildkraut, Joellen M. A1 Thomassen, Mads A1 Simard, Jacques A1 Easton, Douglas F. A1 Jones, Michelle R. A1 Chenevix-Trench, Georgia A1 Gayther, Simon A. A1 Antoniou, Antonis C. A1 Pharoah, Paul D.P. A1 the Ovarian Cancer Association Consortium and the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 YR 2024 UL http://medrxiv.org/content/early/2024/03/04/2024.02.29.24303243.abstract AB Background Nineteen genomic regions have been associated with high-grade serous ovarian cancer (HGSOC). We used data from the Ovarian Cancer Association Consortium (OCAC), Consortium of Investigators of Modifiers of BRCA1/BRCA2 (CIMBA), UK Biobank (UKBB), and FinnGen to identify novel HGSOC susceptibility loci and develop polygenic scores (PGS).Methods We analyzed >22 million variants for 398,238 women. Associations were assessed separately by consortium and meta-analysed. OCAC and CIMBA data were used to develop PGS which were trained on FinnGen data and validated in UKBB and BioBank JapanResults Eight novel variants were associated with HGSOC risk. An interesting discovery biologically was finding that TP53 3’-UTR SNP rs78378222 was associated with HGSOC (per T allele relative risk (RR)=1.44, 95%CI:1.28-1.62, P=1.76×10-9). The optimal PGS included 64,518 variants and was associated with an odds ratio of 1.46 (95%CI:1.37-1.54) per standard deviation in the UKBB validation (AUROC curve=0.61, 95%CI:0.59-0.62).Conclusions This study represents the largest GWAS for HGSOC to date. The results highlight that improvements in imputation reference panels and increased sample sizes can identify HGSOC associated variants that previously went undetected, resulting in improved PGS. The use of updated PGS in cancer risk prediction algorithms will then improve personalized risk prediction for HGSOC.Competing Interest StatementThe authors have declared no competing interest.Funding StatementA complete funding statement can be found in the Acknowledgements and Funding section.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The UKBiobank data have been used under the access application with ID: 28126. All participating studies were approved by the relevant research ethics committee, and all participants provided written, informed consent. Full details are given in the Supplementary Text.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesSummary statistics produced in the present study are available upon reasonable request to the authors.